Scientists Develop Wireless Diabetes Implant That Uses Electricity to Control Blood Sugar - Video

Could a tiny electronic implant control blood sugar and promote weight loss without insulin or conventional diabetes medication? Scientists have developed an experimental device that uses electricity to remove excess glucose from the bloodstream, demonstrating promising results in diabetic mice.

Published in the journal Science, the study conducted by researchers at ETH Zurich in Switzerland investigated a new approach to managing type 2 diabetes through electronically controlled glucose conversion.

Unlike conventional diabetes treatments that help the body absorb or regulate glucose, the experimental implant directly converts excess glucose into gluconate, a substance that can be eliminated through urine.

Researchers developed a specialised catalyst made from graphite felt coated with tiny gold structures and platinum particles.

Importantly, the device operates without living cells, enzymes or other biological components, potentially overcoming some limitations associated with earlier experimental systems.

The implant works alongside a continuous glucose sensor that monitors blood sugar levels.

When glucose concentrations rise, the sensor communicates with a connected smartphone or smartwatch, which activates the implant through a wireless power system.

The catalyst then converts excess glucose into gluconate. Once glucose levels return to the desired range, the system automatically switches off.

Researchers first demonstrated the glucose-conversion process in laboratory experiments before testing the device in diabetic mice.

The findings revealed that the implant successfully regulated blood sugar levels and was also associated with weight loss in the animals.

Importantly, the device continued functioning reliably throughout six weeks of testing and was well tolerated.

Researchers reported no evidence of tissue damage caused by electrical or thermal effects during the experiments.

However, the technology remains experimental and has not been tested in humans.

Further studies are needed to establish its long-term safety, effectiveness and suitability for clinical use.

REFERENCE: Debasis Maity, Preetam Guha Ray, Peter Buchmann, Ghislaine Charpin-El Hamri, Martin Fussenegger. Wireless electrocatalytic closed-loop system for drug-free management of diabesity. Science, 2026; 394 (6822) DOI: 10.1126/science.ady8560